We believe we can leverage our history and knowledge of Rx dermatology to create skincare products that are effective and safe, and available to consumers without the nuisance of obtaining a prescription. We believe this strategic repositioning will accelerate our path to commercialization, reduce our regulatory burden, and decrease development expenses, all while enabling us to address broad consumer segments in the skincare market.
Partnerships Revance Therapeutics: Clinical Trial Collaboration Agreement (Jan 2025) for a Phase 2a trial of Dermata Compound + Daxxify (daxibotulinumtoxinA); royalty-free cross-licenses, no financial consideration; trial on hold. Reka-Farm: exclusive Spongilla raw-material supply; <1% royalty on net sales of Spongilla-containing products.
Indications
Moderate-to-severe acne(Phase 3)
Status note Phase 3 STAR-1 topline reported Q1 2025; filing calls XYNGARI 'formerly its lead prescription candidate' but states no discontinuation or STAR-1 results in these excerpts. Revance Phase 2a combination trial placed on hold. Company also markets the Tome skincare brand (cosmetic).
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.